drug_type
RELEVANT_DRUG
intervention_type
Gene-modified autologous TCR T-cell therapy (cellular immunotherapy)
drug_description
Autologous T-cell receptor–engineered T-cell therapy in which patient T cells are lentivirally transduced ex vivo to express an HLA-A*02:01–restricted TCR that recognizes mutant NPM1 (dNPM1) peptides; the cells are expanded and reinfused to mediate antigen-specific cytotoxicity against NPM1-mutant AML.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Receptors, Antigen, T-Cell
drug_category
ENGINEERED TCR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are lentivirally transduced ex vivo to express an HLA-A*02:01–restricted T-cell receptor specific for mutant NPM1 (dNPM1) peptides; after expansion and reinfusion, these engineered T cells recognize the HLA-A*02:01/dNPM1 peptide complex on NPM1-mutant AML cells and mediate antigen-specific cytotoxic killing.
drug_name
MB-dNPM1-TCR.1
nct_id_drug_ref
NCT06424340